


Listing of the Claims

This listing of claims will replace all prior version, and listings, of claims in the application:

- 1) (Currently amended) A lipid compound represented by the formula



wherein R₁ is a long chain fatty acid, R₂ is a long chain fatty acid, wherein "n" is an integer defining the length of the PEG chain, and

wherein said compound is characterized by the ability to inhibit biological activity of phospholipase A₂.

- 2) (Canceled)
- 3) (Original) The compound of claim 1, wherein said compound is characterized by the ability to inhibit biological activity of cyclooxygenase-2
- 4) (Original) The compound of claim 1, wherein said R1 long chain fatty acid is between 11 and 25 carbons in length.
- 5) (Original) The compound of claim 1, wherein said R2 long chain fatty acid is between 11 and 25 carbons in length.
- 6) (Original) The compound of claim 1, wherein the variable "n" is an integer between 11 and 46.

7) (Previously amended) The compound of claim 1, wherein R1 represents a long chain fatty acid selected from the group consisting of:

- (a) $\text{CH}_3(\text{CH}_2)_{10}$,
- (b) $\text{CH}_3(\text{CH}_2)_{10}(\text{CH})_2(\text{CH}_2)_7$,
- (c) $\text{CH}_3(\text{CH}_2)_{12}$,
- (d) $\text{CH}_3(\text{CH}_2)_{14}$, and
- (e) $\text{CH}_3(\text{CH}_2)_{16}$.

8) (Original) The compound of claim 1, wherein R2 represents a long chain fatty acid selected from the group consisting of:

- (a) $\text{CH}_3(\text{CH}_2)_{10}$,
- (b) $\text{CH}_3(\text{CH}_2)_{10}(\text{CH})_2(\text{CH}_2)_7$,
- (c) $\text{CH}_3(\text{CH}_2)_{12}$,
- (d) $\text{CH}_3(\text{CH}_2)_{14}$, and
- (e) $\text{CH}_3(\text{CH}_2)_{16}$.

9) (Original) The compound of claim 1, wherein the variable "n" is an integer between 11 and 46, and wherein R1 and R2 each represent a long chain fatty acid selected from the group consisting of:

- (a) $\text{CH}_3(\text{CH}_2)_{10}$,
- (b) $\text{CH}_3(\text{CH}_2)_{10}(\text{CH})_2(\text{CH}_2)_7$,
- (c) $\text{CH}_3(\text{CH}_2)_{12}$,
- (d) $\text{CH}_3(\text{CH}_2)_{14}$, and
- (e) $\text{CH}_3(\text{CH}_2)_{16}$.

10) (Canceled)

11) (Canceled)

12) (Canceled)

13) (Canceled)

14) (Canceled)

15) (Canceled)

16) (Canceled)

17) (Canceled)


18) (Canceled)

19) (Canceled)

20) (Canceled)

21) (Canceled)

22) (Currently amended) A composition of matter comprising one or more lipids having the formula



wherein R₁ is a long chain fatty acid, R₂ is a long chain fatty acid, wherein "n" is an integer defining the length of the PEG chain, and

wherein said compound is further characterized by the ability to inhibit biological activity of cyclooxygenase-2.

23) (Canceled)

24) (Canceled)

25) (Previously amended) The composition of matter of claim 1, wherein said composition is a pharmaceutical composition

26) (Original) The composition of matter of claim 25, further comprising a pharmaceutically acceptable carrier.

27) (Previously amended) The composition of matter of claim 1, wherein said composition is a foodstuff.

28) (Previously amended) The composition of matter of claim 1, wherein said composition is a dietary supplement.

29) (Previously amended) The composition of matter of claim 1, wherein said composition is a cosmetic.

30) (Previously amended) The composition of matter of claim 25, further comprising a delivery form selected from the group consisting of: a tablet, a capsule, a syrup, a dragee, a suspension, an elixer, a solution, a powder, granules, an emulsion, microspheres, nanospheres, lipid vesicles, polymeric vesicles, an injectable, an ointment, a cream, a milk, an impregnated pad, a gel, a spray, and a lotion..

31) (Canceled)

32) (Canceled)

33) (Canceled)

34) (Canceled)

35) (Canceled)

36) (Canceled)

37) (Canceled)

38) (Canceled)

39) (Canceled)

40) (Previously amended) A method for treating an inflammation related condition in a mammal comprising the step of administering a composition according to claim 25.

41) (Previously amended) A method for treating an inflammation related condition in a mammal comprising the step of administering a composition according to claim 28.


42) (Canceled)

43) (Canceled)

44) (Canceled)

45) (Canceled)

46) (Previously amended) A method for treating an inflammation related condition in a mammal comprising the step of administering an effective amount of a composition of matter comprising one or more lipids having the formula



Wherein R_1 is a long chain fatty acid, R_2 is a long chain fatty acid, and wherein the variable "n" is an integer between 11 and 46.

47) (Previously amended) The method of claim 46, wherein said composition of matter is a pharmaceutical composition.

48) (Original) The method of claim 46, wherein said composition of matter is a foodstuff.

49) (Original) The method of claim 46, wherein said composition of matter is a dietary supplement.

50) (Original) The method of claim 46, wherein said composition of matter is a cosmetic.

51) (Canceled)

52) (Canceled)

53) (Canceled)

54) (Canceled)

55) (Canceled)

56) (Canceled)

57) (Canceled)

58) (Canceled)

59) (Canceled)

60) (Canceled)